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Abstract
Background: Phenylalanine and tyrosine are precursor amino acids required for the synthesis of dopamine, the main
neurotransmitter implicated in the neurobiology of schizophrenia. Inflammation, increasingly implicated in schizophrenia,
can impair the function of the enzyme Phenylalanine hydroxylase (PAH; which catalyzes the conversion of phenylalanine to
tyrosine) and thus lead to elevated phenylalanine levels and reduced tyrosine levels. This study aimed to compare
phenylalanine, tyrosine, and their ratio (a proxy for PAH function) in a relatively large sample of schizophrenia patients and
healthy controls.
Methods: We measured non-fasting plasma phenylalanine and tyrosine in 950 schizophrenia patients and 1000 healthy
controls. We carried out multivariate analyses to compare log transformed phenylalanine, tyrosine, and phenylalanine:tyr-
osine ratio between patients and controls.
Results: Compared to controls, schizophrenia patients had higher phenylalanine (p,0.0001) and phenylalanine: tyrosine
ratio (p,0.0001) but tyrosine did not differ between the two groups (p = 0.596).
Conclusions: Elevated phenylalanine and phenylalanine:tyrosine ratio in the blood of schizophrenia patients have to be
replicated in longitudinal studies. The results may relate to an abnormal PAH function in schizophrenia that could become a
target for novel preventative and interventional approaches.
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Introduction
Dopamine (DA) is a major neurotransmitter implicated in both
the neurobiology of schizophrenia and the underlying mechanism
of action of antipsychotic medications [1]. In the brain,
phenylalanine hydroxylase (PAH) catalyzes the conversion of the
essential amino acid phenylalanine (Phe) to tyrosine (Tyr). Tyr is
then converted in a two-step enzymatic reaction (catalyzed
sequentially by tyrosine hydroxylase (TH) and aromatic L-amino
acid decarboxylase (L-AAAD)) to DA. Further downstream, two
additional enzymes sequentially convert DA to norepinephrine
(NE) and epinephrine (EP) respectively. Phe and Tyr both cross
the blood-brain barrier [2] and the availability of these precursor
amino acids may impact catecholamine synthesis in the brain [3].
Plasma Phe levels have been reported to be significantly elevated
in schizophrenia patients relative to healthy controls [4,5,6,7];
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however, a few studies failed to find significant differences [8,9,10].
Plasma Tyr has been reported to be reduced in schizophrenia
patients relative to healthy controls [7,10]. DA and other
catecholamine synthesis in the brain may be influenced not only
by the availability of precursor amino acids, but also by the
functional integrity of the various enzymes involved in the
catecholamine synthetic pathway. In the synthesis of catechol-
amines, the committed step is the hydroxylation of Phe to Tyr by
PAH; this step therefore requires strict regulation in order to
ensure adequate homeostatic regulation of Phe [11]. The potential
dire consequences of PAH dysfunction is exemplified by the
metabolic disorder, phenylketonuria (PKU). PKU is characterized
by hyperphenylalaninemia and, if untreated, can result in
profound intellectual disability and neurologic sequelae [12].
Furthermore, the enzymes PAH, TH, and tryptophan-5-mono-
xygenase (TPH; which catalyzes the conversion of tryptophan to
serotonin) require the cofactor 6R-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4) for optimal function and BH4 deficiency can lead
to hyperphenylalaninemia [13]. BH4 is synthesized de novo from
guanosine triphosphate (GTP) which is initially converted to 7,8-
dihydroneopterin triphosphate in a reaction catalyzed by GTP
cyclohydrolase 1 (GTPCH-1); 6-pyruvoyltetrahydropterin syn-
thase (PTPS) then catalyzes the conversion of 7,8-dihydroneop-
terin triphosphate to 6-pyruvoyltetrahydropterin; the third and
final step is the conversion of 6-pyruvoyltetrahydropterin to BH4,
a reaction catalyzed by sepiapterin reductase (SR) [14]. BH4 is
ubiquitous and is likely present in all cells and tissues but current
knowledge of the regulatory mechanism of BH4 in the brain is far
from complete [14]. BH4 also modulates glutamatergic system
function and regulates nitric oxide production [15]. BH4 deficit
has previously been reported in schizophrenia patients relative to
healthy controls [16].
Previous studies that have compared Phe and Tyr blood levels
between schizophrenia patients and healthy controls have been
relatively small with total sample sizes (i.e. cases and controls) less
than 200 [6,7,10]. Some of the previous studies also did not
explicitly indicate whether the diagnosis of schizophrenia was
made by a structured clinical interview or by an unstructured
evaluation by a psychiatrist [10]. In addition, the healthy controls
in the previous studies were not thoroughly screened for mental
illness. The aforementioned factors could have been responsible
for some of the discrepancies in the results of the previous studies.
To overcome the limitations of small sample size, less precise
methods of diagnosing schizophrenia in cases, and failure to
thoroughly rule out the presence of mental illness in healthy
controls, the present study compares plasma Phe, Tyr, and
Phe:Tyr ratio in a large sample of schizophrenia patients
diagnosed by the Structured Clinical Interview for DSM-IV
(SCID) and adequately screened healthy controls. We hypothe-
sized that Phe and Phe:Tyr ratio will be elevated in schizophrenia
patients relative to controls and that Tyr level will be reduced in
schizophrenia patients relative to controls.
Materials and Methods
Participants
The participants and the method of enrollment for this study
have been previously described [17]. Briefly, we recruited 950
schizophrenia patients (ages 18 to 60 years, mean age 38.0611.6
years) and 1000 healthy controls (ages 19 to 60 years, mean age
53.5615.8 years) from the Munich area of Germany. All
participants were white. The diagnosis of schizophrenia in all
patients was confirmed with the SCID [18]. We used the SCID to
confirm the absence of any lifetime psychotic disorder in the
healthy control group. We excluded individuals with schizoaffec-
tive disorder, schizophreniform disorder, substance-induced psy-
chosis, and psychotic disorder NOS. Symptom severity in all
patients was measured using the Positive and Negative Syndrome
Scale (PANSS) [19]. All patients were treated with antipsychotic
medications, the doses of which were expressed in chlorpromazine
equivalents [20]. Blood samples were obtained without any dietary
or fasting protocols. Participants were recruited from inpatient and
outpatient settings.
Ethics Statement
The study procedures were described in detail to all partici-
pants, after which written informed consent was obtained. The
majority of included patients had full capacity to consent. The
ability to consent was determined by a psychiatrist. In exceptional
cases where a patient’s capacity to consent was in doubt, but the
patient and his/her legal guardian wished to participate, written
informed consent was obtained from both the patient and the legal
guardian. The local ethics committee of Ludwig Maximilians
University, Munich, Germany approved the study and it was
determined as exempt by the Institutional Review Board of the
University of Maryland School of Medicine Baltimore, MD, USA.
Plasma Measurement of Phe and Tyr
Blood was obtained via a forearm vein and drawn in EDTA
containing tubes. No fasting protocol was utilized. The samples
were centrifuged for 10 min at 4uC and the resulting plasma
aliquoted into Eppendorf tubes which were frozen immediately at
280uC. Samples were kept frozen at 280uC until analysis. Phe
and Tyr concentrations were determined by high performance
liquid chromatography (HPLC) monitoring their natural fluores-
cence at an excitation wavelength of 210 nm and an emission
wavelength of 302 nm as described by Neurauter et al [21].
100 mL plasma was diluted with 100 mL of 500 mM 3-nitro-L-
tyrosine (internal standard) and 25 mL of 2 M trichloroacetic acid
was used to precipitate and separate proteins. Supernatants of the
samples were diluted 1:25 with 0.015 M potassium dihydrogen-
phosphate after centrifugation and the supernatant was used as
elution buffer on HPLC. An albumin-based calibration mixture
was prepared in parallel to the sera, and it contained 100 mM Phe
and 100 mM Tyr and underwent the same pre-analytical
procedures as plasma specimens.
Statistical Analyses
To estimate the activity of PAH, the ratio of the substrate Phe
versus the concentrations of the enzyme product Tyr (Phe:Tyr
ratio = Phe/Tyr) was calculated [22]. The distributions of Phe,
Tyr, and Phe:Tyr ratio were skewed to the right and we therefore
applied a logarithmic transformation to normalize these variables.
We checked for normality by evaluating histogram plots, skewness,
and kurtosis. We also computed categorical variables by initially
splitting the levels of Phe, Tyr, and Phe:Tyr ratio into four
quartiles after which we combined the lower three quartiles for
Phe and Phe:Tyr ratio and the upper three quartiles for Tyr. The
resulting binary categories contained the upper 25th percentile
and lower 75th percentile for Phe and Phe:Tyr ratio and the upper
75th percentile and lower 25th percentile for Tyr. We used t-tests
and x2 test to compare continuous and categorical demographic
variables between schizophrenia patients and healthy controls. T-
tests were used for unadjusted comparison of log-transformed Phe,
Phe:Tyr ratio, and Tyr between patients and controls and linear
regression analyses were used to compare groups adjusted for
gender, age, education (a proxy for socio-economic status), and
body mass index (BMI). We have presented geometric means with
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95% confidence intervals obtained by exponentiating mean log-
transformed Phe, Phe:Tyr ratio, and Tyr for adjusted and
unadjusted comparisons of the two groups. Post-hoc, we evaluated
the relationship between having a diagnosis of schizophrenia and
Phe and Phe:Tyr ratio in the upper 25th percentile or Tyr in the
lower 25th percentile using x2 test. We calculated odds ratio
associated with Phe and Phe:Tyr ratio in the upper 25th percentile
or Tyr in the lower 25th percentile in schizophrenia patients using
logistic regression adjusted for gender, age, education, and BMI.
All significance levels reported are two-sided with P values ,0.01
considered statistically significant. We carried out all the statistical
analyses using IBM SPSS version 20 (Armonk, NY: IBM Corp).
Results
Sample Characteristics
As shown in table 1, the schizophrenia patients in this sample
were on average 15 years younger, had higher BMI, and less
education compared to the healthy controls. There were more
males among patients than among controls. The mean PANSS
score of 101.5 means that the average patient in this sample can be
classified as ‘‘markedly ill’’ based on the classification by Leucht
et al [23].
Phe, Tyr, and Phe:Tyr Ratio between Groups
Schizophrenia patients had significantly higher Phe (geometric
mean difference 1.26 mmol/L; CI 1.18 to 1.36, p,0.0001) and
Phe:Tyr ratio (geometric mean difference 1.41; CI 1.33 to 1.48,
p,0.0001) compared to healthy controls and this finding persisted
after controlling for gender, age, education, and BMI differences
between the 2 groups (table 2). Tyr levels did not significantly
differ between patients and controls in unadjusted and adjusted
analysis (p = 0.596, p = 0.668 respectively).
Relationship between having a Diagnosis of
Schizophrenia and Percentile Category of Phe, Tyr, and
Phe:Tyr Ratio
From x2 analysis, having a diagnosis of schizophrenia was
associated with Phe level (x2 23.61, p,0.0001) and Phe:Tyr ratio
(x2 199.75, p,0.0001) in the upper 25th percentile and Tyr levels
in the lower 25th percentile (x2 30.33, p,0.0001). There was an
increased likelihood of having Phe levels (OR 1.87; CI 1.43 to
2.43, p,0.0001) and Phe:Tyr ratio (OR 4.27; CI 3.22 to 5.67,
p,0.0001) in the upper 25th percentile in schizophrenia patients
relative to controls. The likelihood of having Tyr levels in the
lower 25th percentile was increased in schizophrenia patients (OR
1.86; CI 1.43 to 2.43, p,0.0001).
Discussion
In this relatively large sample, schizophrenia patients had
significantly higher plasma Phe and Phe:Tyr ratio compared to
healthy controls. Tyr levels did not differ between the two groups;
however, having a diagnosis of schizophrenia was associated with
Tyr in the lower 25th percentile with increased odds of Tyr in the
associated percentile. Our finding of elevated plasma Phe in
schizophrenia is consistent with the results of two previous smaller
studies [6,7]. However, the absence of any statistically significant
difference in plasma Tyr between patients and controls in the
current study differs from the reports by Wei et al [10] and Rao
et al [7], both of which found reduced plasma Tyr levels in
schizophrenia patients.
The relatively raised levels of Phe in schizophrenia patients
could be a result of abnormal metabolism of the essential amino
acid. For example, abnormal Phe kinetics was recently document-
ed in schizophrenia patients relative to healthy controls via the
measurement of radioactive carbon (13CO2) in the breath [13C-
phenylalanine breath test (13C-PBT)] of the subjects after the oral
administration of 13C-phenylalanine [24]. Elevated levels of
Phe:Tyr ratio have been associated with immune activation and
inflammation in individuals suffering from cancer, infection, and





(n = 950) p-value*
Age, years (mean 6 SD) 53.5615.8 38.0611.6 ,0.0001
BMI (mean 6 SD) 24.863.9 27.165.5 ,0.0001
Gender male, n (%) 490 (49.0) 600 (63.2) ,0.0001
Education Level (n, %) ,0.0001
Primary 246 (24.7) 405 (42.7)
Secondary 302 (30.2) 241 (25.4)
Tertiary 451 (45.1) 303 (31.9)
Duration of illness, months (mean 6 SD) – 13.1616.2
Mean dose of antipsychotic in CPZ equivalent
(mean 6 SD)
47561248
PANSS (mean 6 SD)
Positive symptoms – 27.766.4
Negative symptoms – 24.467.5
General – 49.4611.7
Total score – 101.5621.4
*x2 test for categorical variables, t-test for continuous variables.
BMI = body mass index; CPZ = chlorpromazine.
doi:10.1371/journal.pone.0085945.t001
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trauma [21,25,26] and a recent study also found Phe:Tyr ratio to
be increased in patients infected with hepatitis C virus treated with
the immune modulator interferon-a [27]. Furthermore, immune
activation with increased circulating levels of proinflammatory
cytokines have also been consistently reported in schizophrenia
patients [28]. Though speculative, as we did not measure markers
of immune activation such as cytokines, C-reactive protein, or
neopterin, it is possible that an immune activated state in the
schizophrenia patients contributes to the inhibition of PAH and
this in turn could be responsible for the elevated Phe and Phe:Tyr
ratio. Oxidative stress accompanying immune activation of
macrophages (via release of reactive oxygen species and neopterin)
has been demonstrated as the chemical background for the
deactivation of PAH [11], a finding further supported by a study
which found Phe levels to be correlated with the marker of
oxidative stress, isoprostane-8 [21].
PAH also requires the cofactor BH4 for optimal activity and
inflammatory cytokines such as interferon-c (the levels of which
have been reported to be elevated in schizophrenia [28]) stimulate
GTPCH-1, the first enzyme involved in the synthesis of BH4;
however, due to the relative deficiency of an intermediate enzyme,
6-pyruvoyltetrahydropterin synthase, there is reduced BH4
synthesis in immune-activated states [29]. The BH4 synthesized
by other cells can also be degraded by the reactive oxygen species
produced by immune cells [30,31]. Therefore, the elevated Phe
and Phe:Tyr observed in schizophrenia patients in the current
study could also be related to a quantitative and qualitative
deficiency of BH4. A study by Richardson and colleagues [16]
which found reduced plasma BH4 in schizophrenia patients lends
support to this hypothesis.
It is important to note that even though Phe levels are elevated
in schizophrenia patients, the elevated levels observed in our
sample (as well as those by Rao et al [7] and Bjerkenstedt et al [6])
are not of the same severity as in PKU. To illustrate, the patient
with the highest plasma Phe in our sample had a value of
266 mmol/L, a value in the benign hyperphenylalaninemia
phentotypic classification of PKU [32]. Patients with benign
hyperphenylalaninemia may require Phe level monitoring, but do
not need any special dietary modification as is necessary for
individuals with classical PKU [30]. Normal plasma Phe ranges
from 30 to 80 mmol/L [33].
Limitations
Antipsychotic medications (taken by all participants with
schizophrenia and none of the controls) are potential confounders,
as it is conceivable that they may influence levels of Phe and Tyr.
Previous research, however, suggests that increased plasma Phe in
schizophrenia patients is unlikely due to antipsychotic medication
as all the patients in the study by Bjerkenstedt et al [6] were
unmedicated and both medicated and unmedicated patients had
elevated plasma Phe in the study by Rao et al [7]. The cross
sectional design of the study was also a limitation, limiting the
ability to ascribe causality or a direction of effect between illness
and the measured amino acids. Additionally, it would have been
highly informative if we had been able to relate the elevated
Phe:Tyr ratio (a proxy for PAH and GTPCH-1 pathway function)
directly with inflammation, but the unavailability of enough
plasma to assay inflammatory markers (e.g. interleukin-6, highly
sensitive C-reactive protein, or neopterin) was prohibitive. We
were also unable to measure Phe and Tyr centrally (cerebrospinal
fluid- CSF). Although patients differed considerably from controls
on demographic variables, statistical analyses controlled for these
factors.
Another limitation is not using a fasting protocol or gathering
information from food diaries which are potential sources of bias
since food preferences, access, as well as the timing of meals could
differ between medicated patients with schizophrenia and
psychiatrically healthy individuals. Temporal proximity to meals
and the amount of protein/amino acids in the diet do influence
Phe and Tyr levels in humans [34] but a diurnal variation in
amino acid levels also exist and is likely multifactorial [34,35].
With regard to the acute effects of amino acid ingestion on plasma
levels, Leeming et al [36] found that the peak value of plasma Phe
occurred one hour after an oral load of Phe while Tyr peak plasma
levels were observed between two to two and a half hours after an
oral load.
Despite these limitations, the study included several strengths
such as a relatively large sample size, confirmation of schizophre-
nia diagnosis by SCID, exclusion of mental illness (including
personality disorders) in healthy controls, and a low diagnostic
heterogeneity by including only schizophrenia patients. While
acknowledging the limitation of not measuring the amino acids in
the CSF, there is also an advantage to measuring in the blood as it
is less invasive and more practical to monitor blood in patients
rather than the CSF.
Table 2. Unadjusted and adjusted geometric mean differences in Phenylalanine, Tyrosine and Phenylalanine:Tyrosine ratio for
schizophrenia patients vs. healthy controls (reference group is the healthy controls).
Geometric meana
differences 95% CI p-value
Unadjusted
Phenylalanine 1.26 mmol/L 1.18 to 1.36 ,0.0001
Tyrosine 0.98 mmol/L 0.91 to 1.05 0.596
Phenylalanine:Tyrosine ratio 1.41 1.33 to 1.48 ,0.0001
Adjustedb
Phenylalanine 1.19 mmol/L 1.08 to 1.30 ,0.0001
Tyrosine 0.98 mmol/L 0.91 to 1.07 0.668
Phenylalanine:Tyrosine ratio 1.30 1.22 to 1.39 ,0.0001
aBased on back-transformed means of log transformed values.
bAdjusted for gender, age, education and body mass index (BMI).
doi:10.1371/journal.pone.0085945.t002
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In summary we have reported that Phe and Phe:Tyr ratio are
elevated in schizophrenia patients relative to healthy controls, and
that lower levels of Tyr are more common among schizophrenia
patients, findings which we have hypothesized to be likely related
to immune activation and impaired PAH function. Longitudinal
studies with improved methodology (fasting blood levels, account-
ing for diet using food diaries, and measuring markers of
inflammation) are needed to evaluate the effect of changes in
plasma Phe on psychopathology in schizophrenia patients.
Randomized controlled trials of Phe-lowering interventions in
schizophrenia will also contribute to a better understanding of the
effect of Phe homeostasis on schizophrenia and could lead to the
development of novel preventative and treatment strategies for this
highly prevalent and severe mental illness.
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7. Rao ML GG, Strebel B, Bräunig P, Huber G, Klosterkötter J (1990) Serum
amino acids, central monoamines, and hormones in drug-naive, drug-free, and
neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res
34: 243–257.
8. Potkin SG, Cannon-Spoor HE, DeLisi LE, Neckers LM, Wyatt RJ (1983)
Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia. Arch Gen
Psychiatry 40: 749–752.
9. Smeraldi E, Lucca A, Macciardi F, Bellodi L (1987) Increased concentrations of
various amino acids in schizophrenic patients. Evidence for heterozygosity
effects? Hum Genet 76: 138–140.
10. Wei J XH, Ramchand CN, Hemmings GP (1995) Low concentrations of serum
tyrosine in neuroleptic-free schizophrenics with an early onset. Schizophr Res
14: 257–260.
11. Fuchs JE, Huber RG, von Grafenstein S, Wallnoefer HG, Spitzer GM, et al.
(2012) Dynamic regulation of phenylalanine hydroxylase by simulated redox
manipulation. PLoS One 7: e53005.
12. Bilder DA, Burton BK, Coon H, Leviton L, Ashworth J, et al. (2013) Psychiatric
symptoms in adults with phenylketonuria. Mol Genet Metab 108: 155–160.
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